SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: former_pgs who wrote (20080)5/18/2006 4:36:22 PM
From: DewDiligence_on_SI  Respond to of 52153
 
Since PFS precedes survival, it makes sense that there are few (far fewer, imo) survival events that have accrued.

You’re assuming that the overwhelming majority of PFS events are progressions rather than deaths. This is the same implicit assumption I made in #20078.



To: former_pgs who wrote (20080)5/18/2006 4:39:44 PM
From: bio_kruncher  Read Replies (1) | Respond to of 52153
 
DSMB in oncology usually look at survival results for safety purposes even if primary efficacy is something else like PFS or response.
Survival analysis could be more powerful even with fewer events than PFS if the hazard ratio was different.
that is, power also depends on how the events are distributed between the groups ( and over time).

I haven't followed this but i'd lean toward this being a positive event.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News